Skip to content

Pharminent

cropped-banner_frontpage_2026-07-11-2.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Regulatory
  • S16 Ep40: FDA Approval Insights: Zongertinib for HER2 TKD-Mutated NSCLC: With Julia Rotow, MD; and Martin Dietrich, MD, PhD
  • Regulatory

S16 Ep40: FDA Approval Insights: Zongertinib for HER2 TKD-Mutated NSCLC: With Julia Rotow, MD; and Martin Dietrich, MD, PhD

OncLive Podcast

In today's episode, we spoke with Julia Rotow, MD, and Martin Dietrich, MD, PhD.

RegulatoryOncologyRead full story

pharminent March 30, 2026 (Last updated: March 31, 2026)

OncLive Podcast

In today’s episode, we spoke with Julia Rotow, MD, and Martin Dietrich, MD, PhD.

RegulatoryOncologyRead full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Blackstone closes $6.3B fund for life sciences investing
Next: AZ considers filings for long-acting Strensiq follow-up

Related Stories

  • Regulatory

FDA approves MSD’s Keytruda combinations for MIBC

pharminent July 13, 2026
  • Regulatory

FDA freezes CRL trove as ‘radical transparency’ push hits speedbump

pharminent July 9, 2026
  • Regulatory

UK first in Europe to clear Boehringer’s IPF drug Jascayd

pharminent July 9, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.